Gacci et al. reported a meta-analysis on the use of PDE-5 inhibitors in the management of LUTS due to BPH and revealed that PDE-5 inhibitors were especially beneficial in younger age patients40. The gene discussed is PDE5A; the disease is benign prostatic hyperplasia.